43 search results for: Bullous Pemphigoid

Missing material
Content temporarily unavailable
Beyond Signs and Symptoms: Broadening Treatment Goals in Dermatology

Dr Lawrence Eichenfield explores the broadening of treatment goals for long-term disease control, highlighting the importance of this approach in atopic dermatitis. Drs Culton, Elmariah, and Hawkes expand the discussion to further examine specific management goals unique to each skin disease (bullous pemphigoid, prurigo nodularis, and chronic spontaneous urticaria).

Missing material
Content temporarily unavailable
ADVENT at EADV 2025

Join leading dermatologists for educational symposia on atopic dermatitis, bullous pemphigoid, and chronic spontaneous urticaria at the EADV congress in Paris, France.

Missing material
Content temporarily unavailable
Time to Act: Reducing the Impact of Uncontrolled Disease Through Early Intervention

Dr Jason Hawkes describes the importance of early intervention for patients with uncontrolled skin diseases and the effectiveness of evidence-based management strategies, sharing a patient case and his clinical insights with chronic spontaneous urticaria. Drs Eichenfield, Elmariah, and Culton join to review the burdens faced by patients with atopic dermatitis, prurigo nodularis, and bullous pemphigoid, respectively. 

Missing material
Content temporarily unavailable
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation​

This 2-hour educational program delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, bullous pemphigoid, and chronic spontaneous urticaria. It will highlight both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies. Experts will guide the audience through diverse patient cases to illuminate diagnostic nuances and the pathophysiology of each condition. These cases will also highlight the importance of shared decision-making and the broadening of treatment goals beyond symptom control. Dynamic panel discussion and active audience participation will be facilitated through real-time polling and curated Q&A sessions.